12 enero 2015
Researchers have announced results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39 percent in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths. These patients also benefit from a reduction in the amount of atherosclerosis in their vessels. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/l3RjwFTOOd4/150112181327.htm
